Tamoxifen Tablets by British Dragon

Tamoxifen PCT timing is determined by the slowest-clearing compound in the cycle — not by Tamoxifen's own pharmacokinetics. Beginning PCT while significant exogenous androgens remain active suppresses the HPT axis response to SERM stimulation and negates the PCT's purpose. Practical timing guidelines: after Testosterone Propionate or short-ester compounds, begin Tamoxifen 3–4 days after the last injection. After Testosterone Enanthate or Cypionate, wait 14–18 days. After Sustabol 350 (which contains Testosterone Decanoate), wait approximately 21 days. After Decabol 250 (Nandrolone Decanoate), wait 21–28 days. Oral-only cycles: begin Tamoxifen 2–3 days after the last tablet. The 2-week loading period of Tamoxifen means its full HPT axis effect builds during the critical first two weeks of PCT — starting at the correct timing ensures that plateau is reached during the period of active recovery rather than after it.

For prevention of gynecomastia in an aromatizing cycle, aromatase inhibitors (Anastrozole, Exemestane, Letrozole) are superior to Tamoxifen. AIs reduce the total amount of estrogen available in the system — they address the root cause. Tamoxifen blocks estrogen receptors in breast tissue but does not lower circulating estradiol, meaning elevated estrogen continues to act on other tissues and the management is symptomatic rather than systemic. The practical consequence: athletes who use Tamoxifen as the sole on-cycle estrogen control may still experience water retention, blood pressure elevation, and mood effects from circulating estradiol even if breast tissue is protected. AIs are the correct primary on-cycle estrogen management tool. Tamoxifen is the correct breast tissue rescue tool when gynecomastia develops despite AI use, or when an AI is not available or tolerated.

Tamoxifen's primary active metabolites — 4-hydroxytamoxifen and Endoxifen — have half-lives of approximately 7 and 14 days respectively. With half-lives this long, it takes 5–7 half-lives of consistent daily dosing before the compound reaches steady-state plasma concentrations where its HPT axis effect is fully expressed. At 5 half-lives of the 7-day metabolite, that is approximately 35 days — but meaningful activity builds progressively from day one. The practical implication is that Tamoxifen's LH/FSH stimulation is increasing throughout weeks 1–4 of PCT, peaking at steady state after approximately 2 weeks of daily dosing. The 40 mg/day loading dose in weeks 1–2 is specifically designed to accelerate the approach to therapeutically effective plasma levels, providing higher initial concentrations during the early PCT window when testosterone suppression is deepest. Reducing to 20 mg/day at week 3 maintains the steady state established by the loading phase.

Tamoxifen can arrest and partially reverse early-stage gynecomastia if introduced promptly when symptoms appear. At 40 mg/day, consistent Tamoxifen use over 4–8 weeks after early gynecomastia signs (nipple sensitivity, tenderness, minor puffiness) can reduce the glandular tissue that has begun developing by blocking continued estrogenic stimulation. Studies in adolescent pubertal gynecomastia — a mechanistically similar condition — have demonstrated partial regression with Tamoxifen treatment in early stages. However, once glandular proliferation has progressed to established fibrous breast tissue — typically after several months of unmanaged gynecomastia — Tamoxifen can stop further development but cannot reverse the accumulated tissue. Mature gynecomastia is addressed only by surgical excision. The clinical lesson is that early response is critical: Tamoxifen's efficacy for gynecomastia reversal is inversely proportional to how long the glandular development has been allowed to progress.

Tamoxifen modulates estrogen receptor activity in the liver, where estrogen receptors normally regulate growth hormone receptor expression and IGF-1 synthesis. By blocking hepatic estrogen receptor activation, Tamoxifen reduces the liver's production of IGF-1 in response to growth hormone signalling. In a standard PCT following an anabolic steroid cycle without HGH, this IGF-1 reduction has minimal practical impact — the athlete is not relying on circulating IGF-1 as a primary anabolic driver during PCT. The interaction becomes clinically relevant specifically when HGH (Somatrobol) is running concurrently with Tamoxifen. HGH's primary tissue-building and lipolytic effects are mediated through IGF-1; reducing IGF-1 directly reduces the return on the HGH investment. Athletes who run long HGH cycles that span the PCT window should consider Clomiphene-only PCT during the HGH phase, and can introduce Tamoxifen only after the HGH cycle concludes if breast tissue management remains a priority.

Most users notice the first effects within the first one to two weeks of dosing.

The side profile depends on the compound class - the Side Effects section on the product page above covers the exact watchpoints for tamoxifen.

Oral compounds clear within days of the last dose; injectable esters extend detection to weeks or months depending on the ester.

British Dragon Tamoxifen Tablets is available in this shop with international and domestic shipping.